Essential Diagnostic and Management Guidelines for Acute Lymphoblastic Leukemia

Initial Diagnostic Workup

Obtain peripheral blood and bone‑marrow aspirate for cytomorphology, 8–10‑color flow cytometry, conventional karyotyping, FISH, and molecular testing (including BCR‑ABL1); report basic results within 48–72 h and comprehensive results within 1–2 weeks. 1, 2, 3
Perform a baseline complete blood count with differential to quantify peripheral‑blood blast percentage. 4, 5
Order a comprehensive metabolic panel (LDH, uric acid, phosphate, potassium, calcium) to assess tumor‑lysis‑syndrome risk. 4, 5
Include a coagulation panel (PT, PTT, fibrinogen, D‑dimer) to screen for disseminated intravascular coagulation. 4, 6
Record patient ethnicity/race; Hispanic patients have inferior outcomes, higher incidence of Philadelphia‑like ALL, and greater risk of pancreatitis. 5
Document environmental/occupational exposures (e.g., benzene, hydrocarbons, formaldehyde, butadiene, ionizing radiation) as potential leukemogenic factors. 5
Perform chest CT in all T‑cell ALL cases to evaluate mediastinal disease. 6
Conduct a testicular examination in all male patients, especially those with T‑cell ALL. 6
Image liver, spleen, lymph nodes, and other extramedullary sites when clinically indicated. 4, 5

Cytomorphology remains essential for the initial diagnosis of ALL. 1, 3, 5
Multicolor (8–10‑color) flow cytometry on bone‑marrow (or peripheral blood if blasts are sufficient) reliably distinguishes B‑cell, T‑cell, or mixed‑phenotype disease even with limited cellularity. 1, 3, 5
When peripheral blood contains an adequate blast percentage, flow cytometry, FISH, and molecular studies may be performed on blood alone; additional bone‑marrow flow is unnecessary. 5
If bone‑marrow aspiration yields a dry tap or is contraindicated, use peripheral blood for all studies or apply immunohistochemistry on core‑biopsy tissue. 4, 5
Conventional karyotyping must be performed on bone‑marrow (or peripheral blood if marrow unavailable). 4, 5, 7
FISH for BCR‑ABL1 (t 9;22) detects the Philadelphia chromosome in ~25 % of adult ALL, ~3 % of pediatric ALL, and up to 40 % of patients > 50 years. 7, 6
FISH for KMT2A (MLL) translocations (e.g., t 4;11, t 9;11, t 11;19) identifies a poor‑prognosis subgroup. 7, 6
In mixed‑phenotype acute leukemia, mandatory testing includes both BCR‑ABL1 and KMT2A rearrangements. 7, 8
Additional prognostic markers:
- TEL‑AML1 (t 12;21) – favorable; present in ~22 % of children, ~2 % of adults. 6
- E2A‑PBX1 (t 1;19) – adverse implication. 6
- Hyperdiploidy (>50 chromosomes) – favorable; seen in 25 % of pediatric and 7 % of adult cases. 6
- Hypodiploidy – poor prognosis; occurs in 1–2 % of ALL cases. 6

Issue a preliminary report containing cytomorphology and flow‑cytometry results within 48–72 hours of specimen receipt. 2, 3, 9
Deliver a final comprehensive report—including all cytogenetic, molecular, and risk‑factor data—within 1 week (maximum 2 weeks if necessary). 2, 3, 9
Release amended reports immediately when ancillary studies modify the diagnosis or subclassification. 2, 3, 8

Philadelphia‑chromosome‑positive ALL is the highest‑risk cytogenetic subgroup and mandates tyrosine‑kinase‑inhibitor therapy. 6
Additional high‑risk features:
- KMT2A (MLL) gene rearrangements (e.g., t 4;11).
- Hypodiploidy.
Favorable‑risk features:
- Hyperdiploidy (>50 chromosomes).
- TEL‑AML1 (t 12;21) translocation.

Real‑time quantitative PCR is the preferred platform for molecular MRD detection; next‑generation sequencing and digital PCR require further validation. 1, 9

Refer all newly diagnosed ALL patients to specialized cancer centers or university‑affiliated hospitals with dedicated ALL expertise. 1, 2, 9
When immediate referral is planned, defer bone‑marrow aspiration/biopsy until the patient reaches the treatment center to avoid duplicate procedures and unnecessary discomfort. 7, 8
During inter‑facility transfer, provide complete laboratory results, pathology slides, flow‑cytometry data, cytogenetic findings, and a list of pending studies. 7, 8

Screen for active infections in febrile or symptomatic patients and initiate empiric antimicrobial therapy as indicated. 6
Obtain baseline cardiac imaging (e.g., echocardiogram) because anthracyclines are incorporated into virtually all ALL regimens. 6
Monitor closely for tumor‑lysis syndrome, especially in patients with high white‑blood‑cell counts or bulky disease. 4, 5, 6

Do not rely solely on peripheral‑blood flow cytometry when bone‑marrow is readily obtainable; marrow provides a more comprehensive assessment. 5
Avoid using low‑sensitivity MRD assays (e.g., Genescan‑based fragment analysis for FLT3); prefer quantitative PCR. 1, 9
Do not delay rapid BCR‑ABL1 testing in suspected cases, as results dictate the need for tyrosine‑kinase‑inhibitor therapy. 7
Ensure all diagnostic laboratories meet regulatory and accreditation standards. 7, 8
Apply current WHO classification terminology for final diagnosis and disease categorization. 7, 8